But it's important to note that the results don't measure the effectiveness of Avidity's drug on functionality. Nakae, the Chardan analyst, says Avidity will likely test that next. He kept his buy rating on RNA stock and hiked his price target to 60 from 45.
possible patient population only 900 boys at the his stage
like I said it’s not a problem for PER We wait.. big news around the corner
PER Price at posting:
8.0¢ Sentiment: Buy Disclosure: Held
